QIMR Berghofer research has found a new reason why some melanoma patients do not respond well to immunotherapy—a discovery that could lead to better-tailored treatments for the potentially deadly cancer.
Australia has the highest rate of melanoma in the world. The Australian Institute of Health and Welfare estimates there were more than 15,000 cases of melanoma in Australia last year, and more than 1700 deaths.
The research, led by QIMR Berghofer Senior Scientist and Immunology Department Coordinator Professor Mark Smyth, found high levels of the protein CD155 in human melanoma cells made the skin cancer harder to treat with immunotherapy.
“Our study has highlighted the central importance of CD155 to the effectiveness of immunotherapy for patients with metastatic melanoma—something that hasn’t been shown before in humans,” Professor Smyth said.
“The tumour appears to be using the CD155 molecule to escape being hunted down by immune cells, called T-cells, and to also resist being killed off by immunotherapy.”
The CD155 protein is expressed by nearly all cancer cells and less so by normal cells, including some immune cells. It is part of a family of adhesive proteins that are important in cell to cell interaction.
“Modern immunotherapy treatments have been quite successful in helping unleash our immune systems to kill melanoma tumour cells, but in some people the tumour cells remain disguised and treatments don’t work, often leading to death,” Professor Smyth said.
“We found high levels of CD155 in melanoma cells seem to help tumours evade detection by the T-cells and trick them into leaving the tumour alone. The tumour CD155 appears to wound the T-cells during the interaction, reducing their capacity to subsequently recognize and kill tumour cells. Reducing tumour CD155 in people with metastatic melanoma may be a way to improve the effectiveness of immunotherapy for them and save the lives of many more people.”
The researchers used new imaging technology to examine pre-treatment tumour samples collected from patients in Brisbane, Sydney and Italy and correlated the levels of CD155 with the patients’ survival outcomes.
Contributing author and Royal Brisbane and Women’s Hospital Medical Oncologist, Dr. Elizabeth Ahern, said the imaging showed very high levels of CD155 in melanoma cells.
“We found patients with higher levels of the protein had worse health outcomes and didn’t respond well to immunotherapies,” Dr. Ahern said.
“It’s the quantity of CD155 proteins that makes it so immune evasive. It appears the T-cells can’t kill the tumour because the CD155 proteins are unbalancing the T-cells and turning them off before they can do their job. Currently there are no therapeutics used for melanoma that target CD155, so we hope to explore that pathway. We now want to focus on designing new immunotherapies that target the CD155 proteins to get them off the tumour.”
The study findings have been published in the journal Clinical Cancer Research.
The study builds on Professor Smyth’s 2018 research that showed CD155 in both tumour and immune cells was important for tumour growth and spread.
Professor Smyth and his team hope to expand the study to examine if CD155 plays a role in how other cancers respond to immunotherapies.